Cargando…
Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666033/ https://www.ncbi.nlm.nih.gov/pubmed/34895168 http://dx.doi.org/10.1186/s12885-021-09079-7 |
_version_ | 1784614127533031424 |
---|---|
author | Ma, Tai Wu, Zhijun Zhang, Xiaopeng Xu, Hui Feng, Ying Zhang, Cheng Xie, Minmin Yang, Yahui Zhang, Yi Feng, Chong Sun, Guoping |
author_facet | Ma, Tai Wu, Zhijun Zhang, Xiaopeng Xu, Hui Feng, Ying Zhang, Cheng Xie, Minmin Yang, Yahui Zhang, Yi Feng, Chong Sun, Guoping |
author_sort | Ma, Tai |
collection | PubMed |
description | BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric carcinoma. METHODS: Patients with advanced gastric carcinoma from two hospitals (development and validation cohort) were included. Cox proportional hazards regression analysis was conducted to identify independent risk factors for survival. A prognostic nomogram model was developed using R statistics and validated both in bootstrap and external cohort. The concordance index and calibration curves were plotted to determine the discrimination and calibration of the model, respectively. The nomogram score and a simplified scoring system were developed to stratify patients in the two cohorts. RESULTS: Development and validation cohort was comprised of 401 and 214 gastric cancer patients, respectively. Mucinous or non-mucinous histology, ECOG score, bone metastasis, ascites, hemoglobin concentration, serum albumin level, lactate dehydrogenase level, carcinoembryonic antigen level, and chemotherapy were finally incorporated into prognostic nomogram. The concordance indices were 0.689 (95% CI: 0.664 ~ 0.714) and 0.673 (95% CI: 0.632 ~ 0.714) for bootstrap and external validation. 100 and 200 were set as the cut-off values of nomogram score, patients in development cohort were stratified into low-, intermediate- and high-risk groups with median overall survival time 15.8 (95% CI: 12.2 ~ 19.5), 8.4 (95% CI: 6.7 ~ 10.2), and 3.9 (95% CI: 2.7 ~ 5.2) months, respectively; the cut-off values also worked well in validation cohort with different survival time in subgroups. A simplified model was also established and showed good consistency with the nomogram scoring model in both of development and validation cohorts. CONCLUSION: The prognostic scoring model and its simplified surrogate can be used as tools for mortality risk stratification in patients with advanced gastric carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09079-7. |
format | Online Article Text |
id | pubmed-8666033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86660332021-12-13 Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma Ma, Tai Wu, Zhijun Zhang, Xiaopeng Xu, Hui Feng, Ying Zhang, Cheng Xie, Minmin Yang, Yahui Zhang, Yi Feng, Chong Sun, Guoping BMC Cancer Research BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric carcinoma. METHODS: Patients with advanced gastric carcinoma from two hospitals (development and validation cohort) were included. Cox proportional hazards regression analysis was conducted to identify independent risk factors for survival. A prognostic nomogram model was developed using R statistics and validated both in bootstrap and external cohort. The concordance index and calibration curves were plotted to determine the discrimination and calibration of the model, respectively. The nomogram score and a simplified scoring system were developed to stratify patients in the two cohorts. RESULTS: Development and validation cohort was comprised of 401 and 214 gastric cancer patients, respectively. Mucinous or non-mucinous histology, ECOG score, bone metastasis, ascites, hemoglobin concentration, serum albumin level, lactate dehydrogenase level, carcinoembryonic antigen level, and chemotherapy were finally incorporated into prognostic nomogram. The concordance indices were 0.689 (95% CI: 0.664 ~ 0.714) and 0.673 (95% CI: 0.632 ~ 0.714) for bootstrap and external validation. 100 and 200 were set as the cut-off values of nomogram score, patients in development cohort were stratified into low-, intermediate- and high-risk groups with median overall survival time 15.8 (95% CI: 12.2 ~ 19.5), 8.4 (95% CI: 6.7 ~ 10.2), and 3.9 (95% CI: 2.7 ~ 5.2) months, respectively; the cut-off values also worked well in validation cohort with different survival time in subgroups. A simplified model was also established and showed good consistency with the nomogram scoring model in both of development and validation cohorts. CONCLUSION: The prognostic scoring model and its simplified surrogate can be used as tools for mortality risk stratification in patients with advanced gastric carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09079-7. BioMed Central 2021-12-12 /pmc/articles/PMC8666033/ /pubmed/34895168 http://dx.doi.org/10.1186/s12885-021-09079-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ma, Tai Wu, Zhijun Zhang, Xiaopeng Xu, Hui Feng, Ying Zhang, Cheng Xie, Minmin Yang, Yahui Zhang, Yi Feng, Chong Sun, Guoping Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title | Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title_full | Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title_fullStr | Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title_full_unstemmed | Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title_short | Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
title_sort | development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666033/ https://www.ncbi.nlm.nih.gov/pubmed/34895168 http://dx.doi.org/10.1186/s12885-021-09079-7 |
work_keys_str_mv | AT matai developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT wuzhijun developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT zhangxiaopeng developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT xuhui developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT fengying developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT zhangcheng developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT xieminmin developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT yangyahui developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT zhangyi developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT fengchong developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma AT sunguoping developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma |